Denrakibart clinical trials
Also written GSK3858279.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses denrakibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GSK3858279
- 4
Studies by the year they started
5 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses denrakibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic PainTerminatedPhase 2GlaxoSmithKlineNCT05838755Written as GSK3858279
- A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) PainTerminatedPhase 2GlaxoSmithKlineNCT05838742Written as GSK3858279
- Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese ParticipantsCompletedPhase 1GlaxoSmithKlineNCT05174013Written as GSK3858279
- A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)CompletedPhase 1GlaxoSmithKlineNCT03485365Written as GSK3858279 IV
- Effects of Intravenous GSK3858279 on a Battery of Evoked Pain Tests in Healthy VolunteersTerminatedPhase 1GlaxoSmithKlineNCT04114656Written as GSK3858279
Codes
What other systems call denrakibart · ClinicalTrials.gg INT014886
- UNII (FDA) 4K7FCQ266QDENRAKIBARTOne source FDA
- NCI Thesaurus C211732DenrakibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 4K7FCQ266Q | DENRAKIBART | One source FDA |
| NCI Thesaurus | C211732 | Denrakibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.